Menu

1 / 2

‘Compromise patient safety, may cause health hazards’: Delhi HC backs drug controller’s action against unauthorised combination drugs

The Indian Express·Sohini Ghosh·7 months ago
#Yu5ksCTu
Reading 0:00
15s threshold

The Delhi High Court has paved the way for the revocation of licences to manufacture, sell, market and distribute fixed-dose combination (FDC) drugs that have not been approved based on safety and efficacy studies.

The court upheld an order passed by India’s central drug regulator in 2025 prohibiting the sale of unapproved FDC drugs.

Such “unapproved FDCs compromise patient safety and may lead to adverse drug reactions and cause other health hazards due to the absence of scientific validation”, the court said in its order passed on April 21.

An FDC drug is a medicine that contains two or more active pharmaceutical ingredients — chemical compounds in medicines that have an effect on the body — in a single pill, capsule, or shot.

FDCs can reduce the number of pills a patient needs to take each day. At the same time, an FDC could mean that a patient ends up taking a drug they may not need.

The government has been putting combination drugs under scrutiny from time to time.…

Continue reading — create a free account

Join HashtagPLUS to read full articles, follow hashtags, vote, and join the conversation.